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Abstract
Autophagy plays an important role in tumorigenesis. Mitochondrion-associated protein LRPPRC interacts with MAP1S that
interacts with LC3 and bridges autophagy components with microtubules and mitochondria to affect autophagy flux.
Dysfunction of LRPPRC and MAP1S is associated with poor survival of ovarian cancer patients. Furthermore, elevated levels
of LRPPRC predict shorter overall survival in patients with prostate adenocarcinomas or gastric cancer. To understand the
role of LRPPRC in tumor development, previously we reported that LRPPRC forms a ternary complex with Beclin 1 and Bcl-2
to inhibit autophagy. Here we further show that LRPPRC maintains the stability of Parkin that mono-ubiquitinates Bcl-2 to
increase Bcl-2 stability to inhibit autophagy. Under mitophagy stress, Parkin translocates to mitochondria to cause rupture
of outer mitochondrial membrane and bind with exposed LRPPRC. Consequently, LRPPRC and Parkin help mitochondria
being engulfed in autophagosomes to be degraded. In cells under long-term mitophagy stress, both LRPPRC and Parkin
become depleted coincident with disappearance of mitochondria and final autophagy inactivation due to depletion of
ATG5-ATG12 conjugates. LRPPRC functions as a checkpoint protein that prevents mitochondria from autophagy
degradation and impact tumorigenesis.
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Introduction
Autophagy, or self-digestion, is a process that begins with the
formation of isolation membranes that engulf substrates including
dysfunctional organelles, mis-folded/aggregated proteins and/or
other macromolecules to form autophagosomes [1,2]. Then
autophagosomes fuse with lysosomes to generate autolysosomes
in which substrates are degraded [3]. Mitochondrion is one of the
most prominent and vital type of organelles in eukaryotic cells.
During cell cycling, mitochondria are constantly synthesized, used,
damaged and destroyed through autophagy (here referred to as
mitophagy) [4,5]. Parkin, whose mutations may be counted for
Parkinson’s disease in small numbers of patients, has recently been
found to regulate the turnover of mitochondria through mitophagy
[6,7]. The role of autophagy in cancer development has attracted
great attention but is not well understood [8].
LRPPRC is an interactive protein of MAP1S, a mitochondria
and microtubule-associated protein previously named as
C19ORF5 [9–11]. It was suggested that mutations in the
LRPPRC gene cause Leigh syndrome, French-Canadian type
(LSFC), a human disorder characterized with neurodegeneration
and cytochrome c oxidase deficiency [12]. Based on the somatic
mutation data of 17301 genes from 316 ovarian cancer patients
from The Cancer Genome Atlas, mutations in both LRPPRC and
MAP1S were found to reduce the survival of patients [13]. As a
sequence homologue of the microtubule-associated protein
MAP1A and MAP1B, MAP1S similarly interacts with mammalian
autophagy marker LC3 [14–16] and bridges autophagic compo-
nents with microtubules and mitochondria to affect autophagoso-
mal biogenesis and degradation and suppress genome instability
and tumorigenesis [16–18]. Recently, we found that elevated levels
of LRPPRC in prostate adenocarcinomas are closely associated
with poor prognosis of prostate cancer patients [19]. A similar
trend was independently reported in patients with gastric cancer
[20].
To better understand the role of LRPPRC in cancer
development, we have previously reported that LRPPRC associ-
ates with mitochondria, interacts with Beclin 1 and Bcl-2 and form
a ternary complex to maintain the Bcl-2 stability. Suppression of
LRPPRC leads to Bcl-2 degradation that leads to release of more
Beclin 1 to form complexes with PI3KCIII to activate basal levels
of autophagy upstream of the ATG5-ATG12 conjugates-mediated
LC3-I to LC3-II conversion [21]. Since inner mitochondrial
membrane-associated LRPPRC [22] was suggested to interact
with mitophagy initiator Parkin based on Mass Spectrometry
analyses from different labs [23,24] and its suppression led to
enhancement of autophagy degradation of mitochondria in
lysosomes [21], we are triggered to investigate the specific role
of LRPPRC in mitophagy in addition to its general role in the
regulation of basal levels of autophagy.
In this study, we show that LRPPRC interacts with Parkin and
maintains the stability of Parkin that stabilizes Bcl-2 to suppress
autophagy from initiation. Under mitophagy stress, mitophagy
initiator Parkin translocates to depolarized mitochondria to bind
with LRPPRC. Consequently, LRPPRC and Parkin regulate
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VADC1, Drp1 and Mitofusin 1 to initiate autophagy and
mitophagy, and eventually become depleted along their associated
mitochondria in cells under long-term mitophagy stress. There-
fore, LRPPRC protects mitochondria from autophagy degrada-
tion.
Materials and Methods
Antibodies, siRNAs, plasmids, and other reagents
Antibody against LRPPRC (1B8) was a gift from Dr. Serafı´n
Pin˜ol-Roma, The Sophie Davis School of Biomedical Education,
the City College of New York, New York [22]. Antibodies against
human LC3 (NB 100-2331) were purchased from Novus
Biologicals and A&G Pharmaceutical, Inc.. The IgG control
antibodies from mouse (SC-2025) and rabbit (SC-2027), primary
antibodies against b-actin (SC-47778), LRPPRC (mouse,
SC166178; rabbit, SC-66845), ATG5 (SC-33210), Bcl-2 (SC-
7832), p27 (SC-776), Beclin 1 (SC-11427), Mitofusin 1 (SC-
166644), Drp1 (SC-32898), VDAC1 (SC-98708), and GFP (SC-
8334), and siRNA molecules specific to LRPPRC (sc-44734),
Parkin (SC-42158) and random sequence control (sc-44234) were
from Santa Cruz Biotechnology, Inc.. Antibodies against Parkin
(mouse, ab77924; rabbit, ab15954), Pink1 (ab23707) and LAMP2
(ab18528) were from abcam. Antibody against P62 (SQSTN1,
BWL-PW9860) was from Enzo Life Sciences International Inc.
Antibody against Tom20 (612278) was from BD Transduction
Laboratories. HRP-conjugated secondary antibodies against
mouse (#172-1011) and rabbit (#172-1019) were from Bio-Rad.
Rhodamine Red-X goat anti-mouse IgG and Alexa Fluor 633 goat
anti-rabbit IgG (R6393 and A-21070), MitoTracker Red
CMXRos, Lipofectamine 2000 (11668-027) and Oligofectamine
(12252-011) were from Invitrogen. GFP-LC3 [25] and GFP-
Parkin [26] were supplied by Drs. Mizushima and Youle,
respectively. MG-132, Bafilomycin A1, Carbonyl cyanide m-
chlorophenyl hydrazone (CCCP) and 6-hydroxydopamine (6-
OHDA) were from Sigma. The protein G beads were from
Amersham Biosciences.
Figure 1. Long-term mitophagy stress results in depletion of LRPPRC and mitochondria and impairment of autophagy flux. (A)
Immunoblot analysis of lysates from 293T cells treated with 10 mM carbonyl cyanide 3-chlorophenylhydrazone (CCCP) for different lengths of time
(hrs) in the absence (Ctrl) or presence of lysosomal inhibitor Bafilomycin A1 (BAF, 10 mM) for 6 hrs before harvest. No Bafilomycin A1 was added in
two treatments at time zero. (B) Representative TEM imaging of cells as treated in panel (A). No Bafilomycin A1 was added in two treatments at time
zero. Bar = 500 nm. (C) Percentages of area occupied by mitochondria in the TEM images. Data were the average and standard deviation of at least
three repeats and the differences are compared based on Student T-test. *, p value #0.05. **, p value #0.01. (D,E) Immunoblot analyses of lysates
from 293T cells untreated (None) or treated with 100 mM 6-hydroxydopamine (6-OHDA) for different time (hrs) in the absence or presence of
Bafilomycin A1 for 0–6 hrs (D) or 6 hrs before harvest (E).
doi:10.1371/journal.pone.0094903.g001
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Cell transfection and co-immunoprecipitation assay
HeLa cells or HeLa cells stably expressing EGFP-LC3 that was
established as previously described [4,25] were transfected with
siRNA molecules packed with Oligofectamine and/or GFP-Parkin
plasmid [25] packed in Lipofectamine 2000 as we previously
described [4,27]. In order to suppress LRPPRC and overexpress
GFP or GFP-Parkin simultaneously, cell densities were increased
to 50–60% confluence to reduce transfection-induced cell death.
Cell lysates were prepared from attached cells and coimmuno-
precipitation were performed as previously described [28]. Same
amount of cell lysates were subjected to immunoprecipitation with
Figure 2. LRPPRC interacts with mitophagy stress-induced mitochondrion-translocated mitophagy initiator Parkin. (A) Immunoblot
analyses of interaction between LRPPRC and Parkin or Pink 1. Same amount of 293T cell lysates were used to perform immunoprecipitation with
same amount of anti-LRPPRC antibody or mouse IgG control under identical procedure. (B–D) Coimmunoprecipitation analyses of LRPPRC-Parkin
interaction under mitophagy stress. Lysates with equal amount of total proteins prepared from 293T cells untreated or similarly treated with 10 mM
CCCP for 2.5 hrs were immunoprecipitated with anti-LRPPRC or Parkin antibody (B). IgG served as control antibody. The relative amounts of Parkin
bound on LRPPRC (C) or LRPPRC bound on Parkin (D) were quantified against the precipitated amounts of LRPPRC (C) or Parkin (D). The level in the
absence of CCCP is set to 1. **, p value #0.01. (E) A fluorescent imaging analysis showing the colocalization of LRPPRC with GFP-Parkin. CCCP, HeLa
cells transiently expressing GFP-Parkin for 48 hrs were treated with 10 mM CCCP for 2.5 hrs before fixation. Bottom panel is the amplification of the
square in the middle panel. Bar = 10 mm. (F,G) Coimmunoprecipitation analyses of LRPPRC-Parkin interaction in HeLa cells overexpressing GFP-Parkin
untreated or similarly treated with CCCP as shown in (E). GFP-Parkin is coimmunoprecipitated with anti-LRPPRC antibody (F), and the relative
amounts of GFP-Parkin bound on LRPPRC are quantified against the precipitated amounts of LRPPRC (G). The level in the absence of CCCP is set to 1.
**, p value#0.01. (H,I) Fluorescent imaging analyses showing the colocalization of GFP-Parkin and LRPPRC with RFP-LC3 punctate foci (H) or LAMP2-
labelled lysosomes (I) 3 or 12 hrs after exposure to CCCP in the absence (Ctrl) or presence of Bafilomycin A1 (BAF). Bar = 5 mm in (H) and 2 mm in (I).
doi:10.1371/journal.pone.0094903.g002
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equal amounts of specific antibodies and control antibodies (IgG)
from the same species.
Fluorescent microscopy and transmission electron
microscopy
Immunofluorescent stain and mitochondria tracking were
performed and images were captured with the laser scanning
microscope similarly as described [4,25]. HeLa cells grown in 6-
well culture plates were transfected with LRPPRC-specific siRNA
or treated with CCCP in the absence or presence of lysosomal
inhibitor Bafilomycin A1, and then fixed and processed for
examination with a JEM 1010 transmission electron microscope
(JEOL, USA, Inc.) as described [16]. Percentages of areas
occupied by autophagic vacuoles or mitochondria were measured
using the ImageJ program.
Results
Long-term mitophagy stress leads to depletion of
LRPPRC and mitochondria and impairment of
autophagy/mitophagy flux
LRPPRC suppresses the initiation of basal levels of autophagy
and mitophagy via enhancing the stability of Bcl-2 protein [21].
Since LRPPRC is a mitochondrion-associated protein, we were
interested to investigate its role in mitophagy, autophagy for
turnover of mitochondria. As widely done in literatures [29], we
used carbonyl cyanide 3-chlorophenylhydrazone (CCCP), a
chemical causing uncoupling of mitochondrial potential, to induce
mitophagy. We found that short-term CCCP treatment (20 mM
for 6–12 hrs) did not change the levels of LRPPRC and Parkin but
increased levels of ATG5-ATG12 conjugates, LC3-II and protein
Figure 3. Colocalization among LRPPRC, Parkin and Tom20-indicated mitochondria at different times under mitophagy stress. HeLa
cells transiently expressing GFP-Parkin treated with 10 mM CCCP for different times were fixed and stained with antibodies against LRPPRC (blue) and
Tom20 (red). Mitochondrial aggregates carrying both LRPPRC and Parkin signals were shown as white in the Merge panels. Bar = 10 mm.
doi:10.1371/journal.pone.0094903.g003
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aggresomal marker P62 in 293T cells treated with lysosomal
inhibitor Bafilomycin A1, suggesting that autophagy flux was
elevated (Figure 1A). More swollen mitochondria were observed in
cells that received CCCP treatment for 6 hrs than in untreated
cells in the absence of Bafilomycin A1 and much higher
mitochondria mass as reflected by the Tom20 levels remained in
cells received CCCP treatment for 12 hrs than in untreated cells in
the presence of Bafilomycin A1 (Figure 1A–C), suggesting that
initial induction of mitophagy with CCCP may activate mito-
phagy. Since inhibition of lysosomal activity with Bafilomycin A1
was confirmed to have no impact on LRPPRC levels,[21] it is the
long-term CCCP treatment that eventually led to depletion of
LRPPRC and Bcl-2 but did not alter levels of Beclin 1 and P27
levels (Figure 1A), supposing to cause autophagy activation as we
previously reported [16,21]. However, the levels of ATG5-ATG12
conjugates were gradually reduced with prolonged period of
CCCP treatment (Figure 1A). Activation of autophagy mediated
by LRPPRC depletion occurs prior to ATG5-ATG12-mediated
LC3-I to LC3-II conversion [21]. Similar to the situation as shown
in the LRPPRC and ATG5 double knockdown experiments [21],
LC3-II and P62 levels decreased in the absence or presence of
Bafilomycin A1 48 hrs after CCCP exposure (Figure 1A),
indicating an impairment of autophagy flux. Long-term CCCP
treatment eventually led to depletion of mitochondrial mass as
indicated by Tom20 levels in immunoblot and mitochondria-
occupied area under electron microscopy, and mitophagy initiator
Parkin (Figure 1A–C). Therefore, CCCP treatment initially led to
activation of autophagy machinery and long-term CCCP insults
led to depletion of mitochondria and the associated LRPPRC, and
eventually caused impairment of autophagy flux.
Figure 4. Colocalization among Parkin, Tom20-indicated mitochondria and RFP-LC3-labelled autophagosomes at different times
under mitophagy stress. HeLa cells stably expressing RFP-LC3 transiently expressed GFP-Parkin treated with 10 mM CCCP for different times were
fixed and stained with antibodies against Tom20 (blue). Mitochondrial aggregates associating with Parkin signals were shown as cyan in the Merge
panels. Bar = 5 mm.
doi:10.1371/journal.pone.0094903.g004
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Similarly, we treated 293T cells with 6-hydroxydopamine (6-
OHDA), an oxidative toxin to generate experimental models of
Parkinson’s disease that is non-enzymatically oxidized to produce
reactive oxygen species such as hydrogen peroxide to induce
mitophagy [30]. We found that 6-OHDA behaved similar to
CCCP but with accelerated pace, activated autophagy flux at early
stage (Figure 1D) and resulted in reduction of Tom20-indictaed
mitochondria mass and the mitochondrion-associated LRPPRC at
late stage (Figure 1E). The fact that two drugs inducing mitophagy
in different mechanisms have the same impact on LRPPRC levels
and activities of autophagy and mitophagy suggests that LRPPRC
plays a general role in mitophagy.
LRPPRC interacts with mitophagy stress-induced
mitochondrion-translocated mitophagy initiator Parkin
Parkin and Pink1 were previously suggested to interact with
LRPPRC as detected by Mass Spectrometry [23,24,31]. To
understand the role of LRPPRC in mitophagy, we tested the
interaction of LRPPRC with Parkin or Pink1. Co-immunoprecip-
itation of endogenous proteins revealed that LRPPRC interacted
with Parkin but not with Pink 1 (Figure 2A). Upon CCCP
treatment for 3 hrs to induce mitophagy in 293T cells, more
endogenous Parkin proteins were precipitated with similar amount
of immunoprecipitated LRPPRC, or more endogenous LRPPRC
proteins were precipitated with less immunoprecipitated Parkin
(Figure 2B–D). When HeLa cells transiently expressing GFP-
Parkin were induced to commit mitophagy with CCCP for 3 hrs,
Figure 5. Colocalization among Parkin, Tom20-indicated mitochondria and LAMP2-labelled lysosomes at different times under
mitophagy stress. HeLa cells transiently expressing GFP-Parkin treated with 10 mM CCCP for different times were fixed and stained with antibodies
against LAMP2 (red) and Tom20 (blue). Lysosome-contained Parkin-associated mitochondrial aggregates were shown as white in the Merge panels.
All experiments were carried out in the absence of lysosomal inhibitor. Bar = 2 mm.
doi:10.1371/journal.pone.0094903.g005
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the diffusing GFP-Parkin translocated to and colocalized with the
mitochondrion-associated LRPPRC (Figure 2E). The short-term
CCCP treatment did not change the levels of LRPPRC but
dramatically increased the amount of LRPPRC-bound GFP-
Parkin (Figure 2F–G). Thus, Parkin translocates to mitochondrion
to induce rupture of outer mitochondrial membrane [32] and bind
with the exposed inner mitochondrial membrane-associated
LRPPRC under mitophagy stress.
Both LRPPRC and Parkin are co-localized with LC3
punctate foci and LAMP2-labelled lysosomes under
mitophagy stress
When HeLa cells stably expressing RFP-LC3 and transiently
expressing GFP-Parkin were exposure to CCCP for 3 hrs, we
found that both LRPPRC and Parkin were not obviously
colocalized with RFP-LC3 punctate foci even in the presence of
Bafilomycin A1 (Figure 2H), suggesting the damaged parkin and
LRPPRC-associated mitochondria were aggregated but not
packaged into LC3-associated autophagosomes yet. After 12 hrs
exposure to CCCP, colocalization of LRPPRC and Parkin-
associated mitochondria with RFP-LC3 punctate foci were
detected in the absence but became obvious in the presence of
Bafilomycin A1 (Figure 2H, white in merge), indicating the
damaged parkin and LRPPRC-associated mitochondria were
packaged into LC3-associated autophagosomes for effective
turnover. This was further confirmed by the colocalization of
Parkin and LRPPRC-associated mitochondria with LAMP2-
labelled lysosomes (Figure 2I).
Under mitophagy stress, translocation of Parkin to
LRPPRC-associated mitochondria induces mitochondrial
aggregation and consequently degradation of LRPPRC,
Parkin and mitochondria
To understand mutual impact of LRPPRC and Parkin during
mitophagy process, we examined their distribution on mitochon-
dria at different times after exposure to CCCP (Figure 3).
LRPPRC associated with Tom20-labelled mitochondria and
overexpressed GFP-Parkin diffused in cytosol of untreated normal
HeLa cells. GFP-Parkin translocated to LRPPRC-associated
mitochondria and induced mitochondrial aggregation at 3 hrs
after CCCP treatment. Mitochondrial aggregates gradually
disappeared with prolonged periods of CCCP treatment from 6
to 24 hrs. A lot of GFP-Parkin-associated and Tom20-labelled
mitochondrial fragments containing no LRPPRC (yellow foci in
Figure 6. LRPPRC controls the stability of Parkin. (A–D) Immunoblot analyses showing the impact of different levels of Parkin on the levels of
LRPPRC. Equal amount of cell lysates from 293T cells treated with random (Mock) or Parkin-specific siRNA (A) or HeLa cells overexpressing GFP or
GFP-Parkin (C) were analyzed by immunoblot and LRPPRC levels under different conditions were quantified (B,D). n.s., not significant. (E) Immunoblot
analyses showing the impact of different levels of Parkin on the levels of LRPPRC under mitophagy stress. Equal amount of cell lysates from HeLa cells
overexpressing GFP or GFP-Parkin treated with CCCP for different times were analyzed by immunoblot. (F,G) Plots of relative intensities of LRPPRC (E)
or Tom20 (F) in HeLa cells treated as in (E). The intensities in samples at time zero were set to 1. (H) An immunoblot analysis showing that
suppression of LRPPRC resulted in degradation of Parkin. 293T cells were treated with Mock or LRPPRC siRNA for 72 hrs. Equal amount of lysates were
analyzed. (I,J) Plots of relative intensities of LRPPRC (I) or Parkin (J) in 293T cells treated with Mock or LRPPRC siRNA. The intensities in samples
treated with MOCK siRNA were set to 1. Data were the average and standard deviation of at least three repeats and the differences were compared
based on paired T-test. *, p value #0.05; ***, p value #0.0001. (K) Immunoblot analyses showing that overexpression of LRPPRC enhanced the
stability of Parkin. COS7 cells were transiently transfected with plasmids carry only GFP or GFP-LRPPRC for 24 hrs, detached and distributed equally to
8 wells. Each well was treated with cycloheximide (CHX) for different times (hrs). Equal amount of lysates as indicated by total protein concentration
and b-actin control were analyzed. (L) Plots of relative intensities of Parkin in COS7 cells treated as in (K). The intensities in samples at time zero were
set to 1.
doi:10.1371/journal.pone.0094903.g006
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the merge panel) existed at 6 to 24 hrs after CCCP exposure.
Finally, mitochondria and the associated LRPPRC and Parkin
were depleted in cells after 48 hrs CCCP treatment.
Similar to as shown in Figure 2H, most of mitochondria were
associated with Parkin and Parkin-associated mitochondria were
not found to be colocalized with RFP-LC3 punctate foci or
LAMP2-labelled lysosomes in in early time after CCCP exposure
in the absence of Bafilomycin A1 (Figure 4,5). Those mitochondria
were effectively packaged into autophagosomes but not effectively
degraded through lysosomes so that we were able to observe some
mitochondria-containing autophagosomes accumulated at 12 hrs
after exposure (Figure 5). Those mitochondria free of LRPPRC
but associating with Parkin were not colocalized with RFP-LC3
punctate foci or LAMP2-labelled lysosomes at 24 hrs after
exposure (Figure 4,5), indicating a positive role of LRPPRC for
mitochondria to be packaged into autophagosomes. Finally,
mitochondria disappeared 48 hrs after exposure (Figure 4,5).
LRPPRC and Parkin mutually regulate stability of each
other
To understand the relation between LRPPRC and Parkin, we
first changed the levels of Parkin by transfection with a Parkin-
specific siRNA in 293T cells or a plasmid expressing GFP-Parkin
in HeLa cells. Either suppression or overexpression of Parkin
caused no change in LRPPRC levels (Figure 6A–D), suggesting
Parkin did not have impact on the levels of LRPPRC under
normal condition. When HeLa cells overexpressing Parkin were
treated with CCCP, LRPPRC was destabilized and mitophagy
was enhanced because of decrease of Tom20 levels (Figure 6E–G).
Suppression of LRPPRC with LRPPRC-specific siRNA in 293T
cells led to significant decrease of both LRPPRC and Parkin levels
(Figure 6H–J). Overexpression of GFP-LRPPRC increased the
half-life of Parkin from about 6 hrs to more than 24 hrs and
dramatically enhanced the stability of LRPPRC (Figure 6K,L).
Therefore, LRPPRC maintained the stability of Parkin and
mitochondrial translocation of Parkin under mitophagy stress led
to subsequent degradation of both LRPPRC and Parkin.
LRPPRC suppresses autophagy/mitophagy through
controlling the Parkin stability
As an E3 ubiquitin ligase, Parkin binds with Bcl-2 and mono-
ubiquitinates it to enhance its stability [33]. As predicated,
overexpression of Parkin led to increases in Bcl-2 levels in cells
containing either normal or suppressed levels of LRPPRC and
suppression of LRPPRC led to destabilization of Parkin and
further decrease of Bcl-2 levels (Figure 7A,B). Consistent with our
previous report [21], suppression of LRPPRC led to activation of
basal levels of autophagy, and overexpression of Parkin that
caused elevation of Bcl-2 levels led to inhibition of basal levels of
autophagy as indicated by the reduced levels of LC3-II in the
presence of Bafilomycin A1 (Figure 7C,D).
Suppression of LRPPRC caused degradation of Parkin and
further treatment with CCCP resulted in faster degradation of
Parkin (Figure 8A,B). Mitochondria have been suggested to be
docked into autophagosomes via the interaction of ubiquitinated
membrane proteins with LC3-II-interactive substrate receptor
P62. Mitochondria-associated protein Mitofusin 1, Drp1 and
VDAC1 have been confirmed as the substrates of Parkin E3 ligase
and claimed as the P62-interactive membrane proteins but such
claim is still in disputation [7]. When cells with LRPPRC
suppressed were exposed to mitophagy inducer CCCP, activated
E3 ligase activity of Parkin led to decreases in levels of VDAC1,
Drp1 and Mitofusin 1 caused by faster turnover through
autophagy (Figure 8A,B).
As we previously reported [21], LRPPRC suppression led to
autophagy activation as indicated by LC3-II levels in the presence
of Bafilomycin A1 (Figure 8A,B). Activated autophagy reduced the
levels of Tom20 and enhanced the degradation of TOM20-
labelled mitochondria (Figure 8A,B). Prolonged periods of CCCP
treatment led to gradual degradation of Parkin and Tom20-
labelled mitochondria and overexpression of LRPPRC maintained
the stability of Parkin and prevented the degradation of Tom20-
labelled mitochondria (Figure 8C–F).
Discussion
The anti-apoptotic proteins of Bcl-2 family exhibit opposite
impact on autophagy initiation. Our previous report shows that
LRPPRC controls the stability of Bcl-2 to suppress basal levels of
autophagy mainly through the Beclin 1-depdendent PI3K-AKT-
mTOR pathway [21]. Here we demonstrate that LRPPRC
interacts with Parkin and maintains its stability so that the Parkin
substrates including Bcl-2 and Parkin itself are stabilized. Thus,
LRPPRC protects mitochondria from autophagy degradation.
Under mitophagy stress, Parkin translocates to mitochondrion to
induce rupture of outer mitochondrial membrane [32] and bind
Figure 7. LRPPRC maintains levels of Bcl-2 and suppresses
basal levels of autophagy through Parkin. (A) Immunoblot
analyses of Bcl-2 levels in 293T cells overexpressing Parkin in the
absence or presence of LRPPRC siRNA. (B) Plots of relative intensities of
Bcl-2 as shown in (A). The intensities in samples overexpressing GFP
were set to 1. Data were the average and standard deviation of at least
three repeats and the differences were compared based on paired T-
test. *, p value #0.05. (C) Immunoblot analyses of LC3-II levels in 293T
cells treated with either random or LRPPRC-specific siRNAs and/or
overexpressing GFP or GFP-Parkin in the presence of Bafilomycin A1.
(D) Plots of relative intensities of LC3-II as shown in (C). The intensities
in samples treated with random siRNA and overexpressing GFP were set
to 1. Data were the average and standard deviation of at least three
repeats and the differences were compared based on paired T-test. *, p
value #0.05.
doi:10.1371/journal.pone.0094903.g007
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Figure 8. LRPPRC suppresses mitophagy through controlling the Parkin stability. (A,B) Immunoblot analyses of impact of LRPPRC on
Parkin, Parkin substrate VDAC1, Drp1 and Mitofusion, and autophagy/mitophagy in 293T cells. Lysates with equal amount of total proteins were
prepared from cells treated with random (Mock) or LRPPRC-specific siRNA and induced mitophagy with 0 or 10 mM CCCP in the absence or presence
of Bafilomysin A1. Same amounts of cell lysates were subjected to immunoblot analyses (A) and the relative protein levels to those of b-Actin were
plotted (B). **, p value #0.01. (C) Immunoblot analyses of impact of LRPPRC on Parkin and mitophagy in COS7 cells overexpressing GFP or GFP-
LRPPRC treated with 10 mM CCCP for different times (hrs). (D,E) Plots of relative intensity of Parkin (D) or Tom20 (E) for immunoblots shown in (C).
The intensities in samples collected at 0 hr were adjusted based on b-Actin intensity and set to 1. (F) Immunostaining analysis of mitochondrial mass
in COS7 cells similarly treated as in (C) showing the intensities of Tom20-labelled mitochondrial mass. All images were captured under identical
protocol of staining and imaging settings.
doi:10.1371/journal.pone.0094903.g008
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with LRPPRC. Then, LRPPRC, Parkin and other substrates of
Parkin may be ubiquitinated by Parkin E3 ligase and recognized
by autophagy machinery and guide mitochondria to be degraded
through mitophagy.
Parkin is selectively recruited to dysfunctional mitochondria
with low membrane potential in mammalian cells. After recruit-
ment, Parkin mediates the engulfment of mitochondria by
autophagosomes and the selective elimination of impaired
mitochondria [34]. Mitofusin 1 [35], Drp1 [36] and VDAC1 [6]
were reported to be substrates of Parkin while LRPPRC is also
listed as Parkin substrates in the associated online supplementary
although the exact mechanism is still in investigation [37].
Ubiquitinated VDAC1 and Drp1 will cause their associated
mitochondria to be brought into autophagosomes and autolyso-
somes for degradation. Since a significant portion of Bcl-2 is
associated with mitochondria and Parkin-mono-ubiquitinated Bcl-
2 is more stable, suppression of LRPPRC leads to decreases in
levels of Parkin and Bcl-2 and activation of basal autophagy as we
previous reported [21]. Interestingly, Parkin itself is the substrate
of its ligase activity. After auto-ubiquitination, Parkin gradually
becomes depleted along Bcl-2 and ATG5-ATG12 conjugate in
cells under long-term mitophagy stress.
The drug-induced mitophagy stress is an artificially introduced
pathological condition. Under normal physiological condition, it is
unlikely that all of mitochondria in cells are simultaneously
damaged. The drug-induced mitochondrial damages are so
massive that autophagy/mitophagy machinery is incapable of
handing so many damaged mitochondria immediately. This is
possibly the reason that we observed a large amount of
mitochondria aggregates accumulated in the first 12 hrs after
exposure to mitophagy inducer. These mitochondrial aggregates
then become fragmented mitochondria to be engulfed in
autophagosomes and further autolysosomes for degradation.
Parkinson’s disease results from the death of dopamine-
containing cells in the substantia nigra region of the midbrain.
Several mutations in specific genes such as Parkin have been
identified in a few individuals with familial form or autosomal
recessive juvenile Parkinson’s disease [38]. Mitochondrial dys-
function and oxidative stress have long been implicated as the
general pathophysiologic mechanisms underlying Parkinson’s
disease [39]. Impairment of autophagy and mitophagy processes
may be the determining force in the majority of patients to develop
Parkinson’s disease [39].
Interestingly, the same group of proteins involved in juvenile
Parkinson’s disease also plays important roles in tumorigenesis
although the somatic mutations of Parkin identified are homozy-
gous in Parkinson’s disease and heterozygous in cancers [40]. If
the autophagic process is blocked before autophagosomal forma-
tion, the fragmented mitochondria will release cytochrome c and
other molecules to induce apoptosis that is usually associated with
diverse forms of aggregation and perinuclear clustering of the
dysfunctional mitochondria [41,42]. If either the process is blocked
before the autolysosomal formation or autophagosomes are not
degraded efficiently, the accumulated mitochondria may become
damaged by their own production of superoxide and start to leak
electrons and lose their membrane potentials, and even further
induce robust oxidative stress [43]. High levels of oxidative stress
are lethal in post-mitotic neuronal cells in Parkinson’s disease,
while sub-lethal levels of oxidative stress not only induces DNA
double-strand breaks but also weakens mitotic checkpoint function
so that cells carrying damaged genomes can escape mitotic
checkpoint to enter next rounds of mitosis to further destabilize the
genomes and result in tumorigenesis [16–18]. High levels of
LRPPRC maintain Bcl-2 levels, block mitophagy and prevent
mitochondria from autophagy degradation. It has been known
that overexpression of members of the Bcl-2 family of pro-survival
proteins is commonly associated with unfavorable pathogenesis in
cancer [44]. Specifically, high levels of Bcl-2 protein are detected
in androgen-independent tumors in advanced stages of the
pathology [45]. It is well known that most tumor cells need more
energy than their normal mature counterparts [46]. Prostate
cancer, like other cancers, demonstrates abnormal mitochondria
activity [47,48]. Therefore, patients at late stage of prostate
adenocarcinomas exhibit higher levels of LRPPRC than those at
early stage of the disease [19].
Since LRPPRC-Parkin interaction may play important roles in
two seemingly contradicting events of uncontrolled cell growth in
cancers and cell death and neuron degeneration in Parkinson’s
disease, manipulating the interaction provides a new opportunity
to target both diseases. Characterization of exact interactive
domains in both LRPPRC and Parkin proteins may help to
develop drugs to precisely regulate the interaction to differentiate
their specific roles from those played by other interactive proteins.
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